Final results from a large-scale Phase III trial of the RTS,S malaria vaccine candidate, including the impact of a booster dose, published today in The Lancet, show that the vaccine candidate helped protect children and infants from clinical malaria for at least three years after first vaccination. … [Read more...]
Phase III Trial of RTS,S Malaria Candidate Vaccine Reduces Malaria by One Third
Results from a pivotal, large-scale Phase III trial, published online today in the New England Journal of Medicine, show that the RTS,S malaria vaccine candidate can help protect African infants against malaria. When compared to immunization with a control vaccine, infants (aged 6-12 weeks at first vaccination) vaccinated with RTS,S had one-third fewer episodes of both clinical and severe malaria … [Read more...]
Study Finds Malaria Vaccine Candidate, RTS,S Significantly Reduces Malaria Risk in African Infants
First results from a large-scale Phase III trial of RTS,S*, published online today in the New England Journal of Medicine (NEJM), show the malaria vaccine candidate to provide young African children with significant protection against clinical and severe malaria with an acceptable safety and tolerability profile. The results were announced today at the Malaria Forum hosted by the Bill & … [Read more...]
RTS,S Malaria Vaccine
QUESTION: What information can you provide on this vaccine candidate? ANSWER: RTS,S is a vaccine candidate against Plasmodium falciparum malaria which works by encouraging the host's body to produce antibodies and T cells which diminish the malaria parasite's ability to survive and reproduce in the liver. Produced by GlaxoSmithKline, RTS,S is the first vaccine candidate against … [Read more...]
GSK and Johnson & Johnson Announce Malaria Vaccine Collaboration
GlaxoSmithKline Biologicals (GSK Bio) and Crucell NV (Johnson & Johnson) have announced a collaboration to develop a vaccine approach aimed at boosting the efficacy of the world’s most clinically advanced malaria vaccine candidate, RTS,S. The PATH Malaria Vaccine Initiative (MVI) today congratulated the companies on the partnership. "We are excited by the potential of this new endeavor for … [Read more...]
Liquidia Technologies Gets $10M from Gates Foundation for Malaria Vaccine
The Bill & Melinda Gates Foundation invested $10 million in Liquidia Technologies, a closely held biotechnology company developing vaccines, as part of a $400 million initiative to fund activities to help poorer countries. Liquidia is developing a seasonal flu vaccine and has an agreement with the PATH Malaria Vaccine Initiative to use its technology to work on new malaria vaccines, the … [Read more...]
Professor Working on Malaria Vaccine that Will Inoculate Mosquitos When They Bite People
The same menace that spreads malaria – the mosquito bite – could help wipe out the deadly disease, according to researchers working on a new vaccine at Tulane University. The PATH Malaria Vaccine Initiative(MVI), established in 1999 through a grant from the Bill & Melinda Gates Foundation, announced today a collaboration with Tulane University School of Public Health and Tropical Medicine … [Read more...]